Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 9 of 9 results for omega-3-acid

  1. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  2. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

  3. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  4. What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis?

    Question What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and...

  5. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  6. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  7. Familial hypercholesterolaemia: identification and management (CG71)

    This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

  8. Research recommendations

    CG113/3 | For people with generalised anxiety disorder (GAD) who are ready to start

  9. Offer cardiac rehabilitation 'as soon as possible' to heart attack patients

    Cardiac rehabilitation should be offered as soon as possible to people who have had an myocardial infarction (MI) to help them get back to everyday life as quickly as possible, says NICE.